[EN] USE OF A NEW CLASS OF NUCLEOTIDE SUGAR AS ANTIBIOTIC OR CYTOSTATIC AGENT<br/>[FR] UTILISATION D'UNE NOUVELLE CATÉGORIE DE SUCRE DE NUCLÉOTIDE EN TANT QU'ANTIBIOTIQUE OU AGENT CYTOSTATIQUE
申请人:MAX PLANCK GESELLSCHAFT
公开号:WO2012038097A1
公开(公告)日:2012-03-29
The present invention relates to the use of a compound of the formula (A), its use in medicine and for the prophylaxis and/or treatment of infectious diseases. Also disclosed are pharmaceutical formulations containing at least one of the inventive compounds. The compounds are especially useful for prophylaxis and/or treatment of bacterial infection. Further part of the invention is a method for producing the compounds of the formula (A)
The present invention relates to novel substituted sulfoximine derivatives of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.
The invention provides compounds and compositions that are useful for treating conditions including Alzheimer's disease, Parkinson's disease, diabetes, cancer, and psychotic disorders such as schizophrenia.
Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
申请人:——
公开号:US20030191115A1
公开(公告)日:2003-10-09
The present application describes lactam-containing compounds and derivatives thereof of Formula I:
1
or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
申请人:Bristol-Myers Squibb Company
公开号:US20170050964A1
公开(公告)日:2017-02-23
The present application describes lactam-containing compounds and derivatives thereof of Formula I:
P
4
—P-M-M
4
I
or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.